Barry Berkowitz, Ph.D.
University of California, San Francisco. Adjunct Professor of Pharmacology. Founder, Chairman, and Chief Executive Officer, Strong Pharma, LLC. Strong has founded several companies including: Myco/ChemGenics, Fibrogen and New Chemical Entities (sold to Albany Molecular). Strong is currently organizing a new company which utilizes a compelling and novel business model to increase the efficiency of and accelerate drug development.
Tsuneya Ikezu, M.D., Ph.D.
Mayo Clinic, Adjunct Professor of Pharmacology. Professor of Neuroscience and Director of Mayo’s Clinic Molecular NeuroTherapeutics Laboratory.
Research interests: Neuroimmune cell-mediated regulations of neuronal function, neurogenesis, neuroinflammation and neurodegeneration. Particularly interested in how the innate immune-related cells, extracellular vehicles (EVs) and molecules in the central nervous system (CNS) influence the pathology and progression of select neurodegenerative disorders such as Alzheimer’s disease (AD) and frontotemporal dementia.
Marion Kasaian, Ph.D.
Case Western Reserve University. Adjunct Associate Professor of Pharmacology. Principal Research Scientist IV, Inflammation and Immunology, Pfizer Global Biotherapeutic Technologies, Pfizer, Inc., Cambridge, MA.
Research interests: Cellular and innate immune mechanisms contributing to inflammatory diseases, with a focus on asthma.
Oberlin College; M.D. Boston University School of Medicine, Ph.D. Boston University. Adjunct Associate Professor of Pharmacology, School of Medicine; Professor of Anesthesia, Harvard Medical School.
Research Interests: the pharmacokinetics and pharmacodynamics of opioids and sedative hypnotic drugs.